PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30

Propanc Biopharma, Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026

$0.32−0.03 (-7.31%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Propanc Biopharma, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30	FY 2010 2010-06-30	FY 2009 2009-06-30
Cost of Revenue	–	–	–	–	–	–	–	0.03	0.03	0.03	–	–	–	–	–	–	–	–
Research & Development	0.63	0.22	0.25	0.25	0.26	0.23	0.18	0.26	1.83	0.97	1.45	0.13	0.01	0.01	0.01	0.39	–	–
General & Administrative	0.67	0.11	1.25	1.50	1.71	1.55	3.28	2.33	2.10	4.74	5.43	1.57	0.74	1.34	12	1.84	–	–
Operating Expenses	18	57	1.54	1.78	1.99	1.81	3.49	2.61	3.96	5.74	6.90	1.71	0.76	1.36	12	2.24	–	–
Operating Income	-18	-57	-1.54	-1.78	-1.99	-1.81	-3.49	-2.61	-3.96	-5.74	-6.90	-1.71	-0.76	-1.36	-12	-2.24	–	–
Interest Expense	0.43	0.56	0.67	0.53	0.57	0.45	1.75	1.31	2.79	3.20	4.49	1.32	0.09	0.01	0.00	–	–	–
Interest & Investment Income	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0	0.00	0.00	–	–
Other Non-Operating Income	-0.68	-1.65	-0.41	-1.01	-0.72	-0.33	-1.38	-3.26	-3.26	-2.43	-2.59	-1.78	-0.12	-0.14	-0.02	0.00	–	–
Legal Settlements	–	–	–	–	–	–	–	0.01	-0.02	-0.20	–	–	–	–	–	–	–	–
Pretax Income	-19	-59	-1.95	-2.79	-2.71	-2.14	-4.88	-5.76	-7.04	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	-0.13	-0.13	-0.05	-0.11	-0.13	-0.12	-0.18	-0.31	-0.07	-0.08	-0.05	-0.06	-0.17	-0.08	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-2.03	-4.74	–	–	–	–	–	–	–	–	–	–	–
Net Income	-19	-59	-1.82	-2.66	-2.66	-2.03	-4.74	-5.76	-7.04	-7.87	-9.41	-3.41	-0.83	-1.44	-11	-2.15	-0.84	-0.44
Preferred Dividends	0.93	–	0.19	0.47	0.70	0.39	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-20	-59	-2.01	-3.13	-3.36	-2.42	-4.74	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-17.62	-371.22	-1,420.53	-107,969.40	-2,952,963.09	-47,986.40	-11,543,728.35	-658,013.51	-10,721,961.25	-67,180,960.00	-144,858,945.00	-149,957,500.00	-74,978,750.00	-149,957,500.00	-1,199,660,000.00	-224,936,250.00	–	–
EPS (Diluted)(per share)	-17.62	-371.22	-1,420.53	-107,969.40	-2,952,963.09	-47,986.40	-11,543,728.35	-658,013.51	-10,721,961.25	-67,180,960.00	-144,858,945.00	-149,957,500.00	-74,978,750.00	-149,957,500.00	-1,199,660,000.00	-224,936,250.00	–	–
Shares Outstanding (Basic, Weighted)(shares)	1.12	0.16	0.00	0.00	0.00	0.00	0	0.00	0.00	0	0	0	0	0	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	1.12	0.16	0.00	0.00	0.00	0.00	0	0.00	0.00	0	0	0	0	0	–	–	–	–
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	-1.36	-12	-2.23	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -161.9%

Financial strength

Current ratio: 2.55
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 24.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –